10-Q: Surmodics Reports Q3 2024 Results Amidst Pending Acquisition

Surmodics' Q3 2024 results show a significant revenue decrease due to a prior year milestone payment, alongside increased product sales and a pending merger agreement.

Summary

• Surmodics reported a revenue of $30.3 million for the third quarter of fiscal year 2024, a 42% decrease compared to the same period last year, primarily due to a $27 million milestone payment from Abbott in Q3 2023.
• The company's nine-month revenue for fiscal year 2024 was $92.9 million, an 11% decrease year-over-year.
• Medical device product sales increased by 15% in Q3 2024 and 32% for the first nine months of 2024, driven by SurVeil DCB and Pounce thrombectomy products.
• Performance coating royalties and license fees increased by 13% in Q3 2024 and 17% for the first nine months of 2024, primarily due to the Serene hydrophilic coating.
• SurVeil DCB license fee revenue decreased significantly due to the prior year's milestone payment, with $1.1 million in Q3 2024 compared to $25.9 million in Q3 2023.
• In Vitro Diagnostics (IVD) revenue increased by 8% in Q3 2024 and 6% for the first nine months of 2024, driven by product sales.
• The company reported a net loss of $7.6 million for Q3 2024 and $8.1 million for the first nine months of 2024.
• Operating expenses increased, with SG&A rising by 29% in Q3 2024 due to merger-related charges.
• The company is in the process of being acquired by BCE Parent, LLC for $43.00 per share in cash, with the merger expected to close by February 28, 2025, subject to shareholder and regulatory approvals.

Sentiment

Score: 4

Explanation: The document presents mixed results with a significant revenue decline offset by product sales growth and a pending acquisition. The net loss and increased expenses temper the positive aspects, resulting in a slightly negative sentiment.

Positives

• Medical device product sales showed strong growth, increasing by 15% in Q3 2024 and 32% for the first nine months of 2024.
• Performance coating royalties and license fees increased by 13% in Q3 2024 and 17% for the first nine months of 2024.
• In Vitro Diagnostics (IVD) revenue increased by 8% in Q3 2024 and 6% for the first nine months of 2024.
• The company has launched the Pounce LP Thrombectomy System and the Pounce Venous Thrombectomy System, and the Sublime microcatheter.

Negatives

• Total revenue decreased by 42% in Q3 2024 compared to Q3 2023, primarily due to a large milestone payment in the prior year.
• SurVeil DCB license fee revenue decreased significantly from $25.9 million in Q3 2023 to $1.1 million in Q3 2024.
• The company reported a net loss of $7.6 million for Q3 2024 and $8.1 million for the first nine months of 2024.
• SG&A expenses increased by 29% in Q3 2024 due to merger-related charges.

Risks

• The merger with BCE Parent, LLC is subject to various closing conditions, and there is no guarantee it will be completed.
• The company is subject to restrictions on its business operations due to the pending merger.
• The company may incur significant transaction costs related to the merger, regardless of whether it closes.
• The company's reliance on a small number of significant customers, including Abbott and Medtronic, poses a risk to its financial results.
• The company faces risks related to the development, regulatory approval, and commercialization of its products.
• The company's ongoing operating losses and interest expenses could impact its growth initiatives.
• The company is exposed to increasing Euro currency risk with respect to its manufacturing operations in Ireland.

Future Outlook

The company anticipates an increase in SG&A expenditures in fiscal 2024 due to merger-related charges and continued commercialization efforts. R&D expenses are expected to remain significant, primarily related to medical device product development. The company believes its existing cash, investments, and credit facilities will provide sufficient liquidity for fiscal 2024.

Management Comments

• The company believes its strategy of developing its own medical device products has increased, and will continue to increase, its relevance in the medical device industry.
• The company is focused on commercializing its vascular intervention medical device products, including the SurVeil DCB, Pounce thrombectomy platform, and Sublime radial access platform.
• The company is actively managing its access to capital to support liquidity and continued growth.

Industry Context

The medical device industry is characterized by high R&D costs, lengthy regulatory approval processes, and reliance on key customers. Surmodics' focus on proprietary coating technologies and vascular intervention devices aligns with industry trends towards innovative and minimally invasive treatments. The pending acquisition reflects a broader trend of consolidation in the medical device sector.

Comparison to Industry Standards

• Surmodics' revenue decline in Q3 2024 is largely attributed to the non-recurring milestone payment in the prior year, which is not typical for most medical device companies.
• The company's product sales growth in the medical device segment is a positive sign, indicating market acceptance of its Pounce and Sublime platforms, which is comparable to other companies launching new products.
• The company's gross margins are being impacted by the shift towards vascular intervention devices, which is a common challenge for companies scaling up production of new products.
• The increase in SG&A expenses due to merger-related charges is specific to Surmodics and not a general industry trend.
• The company's reliance on Abbott for SurVeil DCB distribution is similar to other companies that partner for commercialization, but it also introduces a dependency risk.

Corporate Governance

Legal Proceedings

• The company is involved in various legal actions from time to time, including intellectual property and employment disputes.

Stakeholder Impact

• Shareholders will be impacted by the pending merger, which will result in a cash payment of $43.00 per share if completed.
• Employees may experience uncertainty due to the pending merger, which could affect retention and recruitment.
• Customers and suppliers may be impacted by the merger, potentially leading to changes in business relationships.
• The company's financial performance will impact its ability to invest in future growth and product development.

Next Steps

• The company will continue to manufacture and ship commercial units of the SurVeil DCB to Abbott.
• The company will continue to advance the commercialization of its Pounce thrombectomy and Sublime radial access product platforms.
• The company will seek shareholder approval for the merger with BCE Parent, LLC.
• The company will work to satisfy all closing conditions for the merger.

Key Dates

Keywords

Surmodics, Merger, Medical Devices, In Vitro Diagnostics, Drug-Coated Balloon, Thrombectomy, Revenue, Financial Results, Pounce, Sublime, Abbott, License Fees, Royalties